Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Metabolic

AOD-9604

A synthetic peptide based on the C-terminal fragment (177-191) of human growth hormone, studied in pre-clinical lipolysis research.

Education Hub

Pre-clinical mechanism

Animal models suggest lipolytic and anti-lipogenic activity through pathways distinct from full-length GH, without significant elevation of IGF-1 in early pharmacology.

Key pre-clinical findings

  • Rodent obesity model: dose-dependent reductions in adipose mass without IGF-1 elevation (Heffernan et al., 2001).

Primary literature

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice

Heffernan M, Summers RJ, Thorburn A, et al. · Endocrinology · 2001

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer